|
SML0152
|
|
AK-7 ≥98% (HPLC)
|
AK-7 is a brain penetrant selective SIRT2 inhibitor. No inhibition of SIRT1 or SIRT3 detected. Selective SIRT2 Inhibitor
|
|
|
|
|
|
A8236
|
|
AN-9 ≥95% (HPLC)
|
HDAC Inhibitor tested as an anti-cancer drug; butyric acid pro-drug
|
|
|
|
|
|
SML0209
|
|
ANA-12 ≥98% (HPLC)
|
The neurotrophin brain-derived neurotrophic factor (BDNF) and its receptor tropomyosin-related kinase B (TrkB) have emerged as key mediators in the pathophysiology of several mood disorders, including anxiety and depression. ANA-12 is a TrkB ligand that prevents activation of the receptor by BDNF with a high potency. It binds selectively to TrkB and inhibits processes downstream of TrkB without altering TrkA and TrkC functions. In adult mice model ANA-12 decreases TrkB activity in the brain without affecting neuronal survival. Mice dosed with ANA-12 show reduced anxiety- and depression related behaviors on a variety of tests predictive of anxiolytic and antidepressant properties in humans. ANA-12 may be a valuable tool for studying BDNF/TrkB signaling and may constitute a lead compound for developing the next generation of therapeutic agents for the treatment of mood disorders. There is also N-T19, which is less potent.
|
|
|
|
|
|
284599
|
|
Anabasine ≥97%
|
|
mouse ... Chrna1(11435), Chrna7(11441)
|
|
|
|
|
A5656
|
|
(±)-Anabasine ≥90% (TLC), liquid
|
Tobacco alkaloid; potent nicotinic acetylcholine receptor agonist.
|
mouse ... Chrna7(11441), Chrnb1(11443)
|
|
|
|
|
A7236
|
|
Anacardic acid ≥98% (HPLC)
|
Anacardic acid is a HAT (Histone Acetyltransferase) inhibitor.
|
|
|
|
|
|
A8598
|
|
Ancitabine hydrochloride
|
Antineoplastic
|
|
|
|
|
|
A7505
|
|
1,4-Androstadiene-3,17-dione
|
|
human ... CYP19A1(1588)
|
|
|
|
|
A0887
|
|
5α-Androstane
|
|
human ... UGT1A4(54657)
|
|
|
|
|
A7755
|
|
5α-Androstane-3α,17β-diol
|
Dihydroandrosterone is a testosterone metabolite; affects sperm maturation and survival.
|
rat ... Ar(24208)
|
|
|
|
|
A2480
|
|
5α-Androstan-3β-ol powder
|
mCAR (constitutive androstane receptor) inverse agonist; testosterone metabolite.
|
|
|
|
|
|
A8380
|
|
5α-Androstan-17β-ol-3-one ≥97.5%
|
Androstanolone is an anabolic steroid. Testosterone secreted by the testis is converted to dihydrotestosterone in the target tissues where it appears to mediate many of the biological actions of testosterone. Androgens direct the development of the male phenotype during embryogenesis and at puberty.
|
human ... AR(367), ESR1(2099), PGR(5241), SERPINA6(866), SHBG(6462) mouse ... Esr1(13982) rat ... Ar(24208), Esr1(24890), Nr3c1(24413), Nr3c2(25672), Pgr(25154)
|
|
|
|
|
31573
|
|
5α-Androstan-17β-ol-3-one VETRANAL™, analytical standard
|
|
human ... AR(367), ESR1(2099), PGR(5241), SERPINA6(866), SHBG(6462) mouse ... Esr1(13982) rat ... Ar(24208), Esr1(24890), Nr3c1(24413), Nr3c2(25672), Pgr(25154)
|
|
|
|
|
A7883
|
|
5α-Androst-16-en-3α-ol
|
5alpha-androst-16-en-3alpha-ol (androstenol), is an androgen believed to act as a pheromone.
|
|
|
|
|
|
A3009
|
|
4-Androsten-11β-ol-3,17-dione
|
11β-Hydroxy-4-androstene-3,17-dione is a naturally occurring steroid that is primarily, if not strictly, produced in adrenal tissue1. In diseases such as Cushing′s syndrome, adrenal-originated hyperandrogenism, and congenital adrenal hyperplasia, plasma 11β levels are very high. Plasma 11β concentration is very low in congenital 11-hydroxylase deficiency and adrenal insufficiency.
|
|
|
|
|
|
A9295
|
|
4-Androsten-4-ol-3,17-dione acetate
|
|
|
|
|
|
|
A8008
|
|
5α-Androst-16-en-3-one
|
|
|
|
|
|
|
31579
|
|
Androsterone VETRANAL™, analytical standard
|
|
human ... SERPINA6(866) rat ... Ar(24208)
|
|
|
|
|
E3375
|
|
trans-Androsterone
|
|
human ... HSD17B3(3293)
|
|
|
|
|
A0956
|
|
Angelicin
|
Angular furocoumarin with diverse photobiological effects. Upon long-wavelength UV irradiation, forms monoadduct with double-stranded DNA and reacts with unsaturated fatty acids. Inhibits DNA and RNA synthesis and cell replication in Ehrlich ascites tumor cells.
|
|
|
|
|
|
A0773
|
|
Angiotensin Converting Enzyme Inhibitor ≥95% (TLC)
|
|
|
|
|
|
|
A6402
|
|
[Asn1, Val5]-Angiotensin II ≥97% (HPLC)
|
Synthetic angiotensin agonist that is involved in the regulation of blood pressure, water consumption, and hydromineral balance in fish.
|
human ... AGTR1(185) mouse ... AGTR1(11607) rat ... AGTR1(24180)
|
|
|
|
|
A9900
|
|
[Sar1, Thr8]-Angiotensin II acetate salt hydrate ≥97% (HPLC)
|
Potent, long-acting antagonist of angiotensin II.
|
human ... AGTR1(185), AGTR2(186), AGTRAP(57085) mouse ... AGTR1(11607), AGTR1B(11608), AGTR2(11609), AGTRAP(11610) rat ... AGTR1(24180), AGTR1B(81638), AGTR2(24182), AGTRAP(298646)
|
|
|
|
|
A2275
|
|
[Sar1, Val5, Ala8]-Angiotensin II acetate salt hydrate ≥97% (HPLC), powder
|
Competitive angiotensin II antagonist; inhibits pressor effects of angiotensin II in rats and lowers blood pressure in humans.
|
human ... AGTR1(185) rat ... Agtr1(24180)
|
|
|
|
|
A2900
|
|
[Val5]-Angiotensin II acetate salt hydrate ≥95% (HPLC), powder
|
Angiotensin II analog that is an agonist AT1 angiotensin receptors.
|
human ... AGTR1(185) mouse ... AGTR1(11607) rat ... AGTR1(24180)
|
|
|
|
|
A6563
|
|
6-Anilinoquinoline-5,8-quinone ≥95% (TLC), solid
|
Blocks cGMP production; inhibits intracellular Ca2+ release; blocks the effects of nitric oxide. Inhibits antigen-induced leukotriene release.
|
|
|
|
|
|
A9950
|
|
Aniracetam ≥98%
|
Cognition enhancer (nootropic) that potentiates AMPA receptor mediated ion conductance and potentiates metabotropic glutamate receptor activity.
|
human ... GRM1(2911), GRM2(2912), GRM3(2913), GRM4(2914), GRM5(2915), GRM6(2916), GRM7(2917), GRM8(2918) rat ... Gria1(50592)
|
|
|
|
|
SRA1
|
|
Anisaldehyde solution
|
|
human ... CYP1A2(1544)
|
|
|
|
|
97063
|
|
p-Anisaldehyde analytical standard
|
|
human ... CYP1A2(1544)
|
|
|
|
|
W267007
|
|
p-Anisaldehyde ≥97.5%, FCC
|
Odor at 1.0% Taste at 5-10 ppm
|
human ... CYP1A2(1544)
|
|
|
|
|
A9789
|
|
Anisomycin from Streptomyces griseolus ≥98% (HPLC), solid
|
Antibiotic isolated from Streptomyces griseolus that inhibits protein synthesis. Acts by inhibiting peptidyl transferase activity in eukaryote ribosomes. Reported to induce apoptosis in a variety of cells including promyelocytic leukemia cells, Jurkat cells, ventricular myocytes, and colon adenocarcinoma cells. Initiates intracellular signals and immediate early gene induction. Selective signaling agonist. Potent Jun-NH2 terminal kinase (JNK) agonist. Activates mitogen-activated protein (MAP) kinases (JNK/SAPK and p38/RK). Antiprotozoal agent.
|
|
|
|
|
|
A2836
|
|
Ansamitocin P-3 from Actinosynnema pretiosum ≥90% (HPLC)
|
Fungal metabolite with antineoplastic, antimitotic activity. Binds to tubulin and inhibits vinblastine-induced spiral formation.1
|
|
|
|
|
|
A8727
|
|
Antalarmin hydrochloride ≥98% (HPLC), solid
|
Antalarmin hydrochloride is a non-peptide CRF1 corticotropin-releasing factor receptor antagonist.
|
|
|
|
|
|
A9899
|
|
Antazoline hydrochloride
|
Imidazoline agonist; more potent than efaroxan in inducing insulin release from β cells; H1 histamine receptor antagonist.
|
human ... HRH1(3269)
|
|
|
|
|
A7475
|
|
Anthopleurin-A >88% (HPLC)
|
Shown to have inotropic effects and not chronotropic effects on mammalian heart preparations.
|
|
|
|
|
|
31581
|
|
Anthracene analytical standard, for environmental analysis
|
|
human ... CYP1A2(1544)
|
|
|
|
|
48567
|
|
Anthracene analytical standard
|
|
human ... CYP1A2(1544)
|
|
|
|
|
10580
|
|
Anthracene puriss., suitable for scintillation, ≥99.0% (GC)
|
|
human ... CYP1A2(1544)
|
|
|
|
|
331481
|
|
Anthracene zone-refined, ≥99%
|
|
human ... CYP1A2(1544)
|
|
|
|
|
141062
|
|
Anthracene ReagentPlus®, 99%
|
|
human ... CYP1A2(1544)
|
|
|
|
|
A89200
|
|
Anthracene reagent grade, 97%
|
|
human ... CYP1A2(1544)
|
|
|
|
|
40076
|
|
Anthracene solution 1000 μg/mL in acetone, analytical standard
|
|
human ... CYP1A2(1544)
|
|
|
|
|
48647
|
|
Anthracene solution 200 μg/mL in methanol, analytical standard
|
|
human ... CYP1A2(1544)
|
|
|
|
|
A9285
|
|
α1-Antichymotrypsin from human plasma ≥92.5% (SDS-PAGE), lyophilized powder
|
Specific inhibitor of chymotrypsin-like serine proteases. Promotes amyloid-β polymerization in vitro and in vivo. Levels in plasma and cerebrospinal fluid have been found to correlate with progression of dementia in Alzheimer′s patients1 and induce phosphorylation of tau protein in neurons.2
|
human ... SERPINA3(12)
|
|
|
|
|
A8802
|
|
Antide ≥97% (HPLC)
|
LH-RH antagonist with high anti-ovulatory and negligible histamine release activity.
|
rat ... Gnrhr(81668)
|
|
|
|
|
A8674
|
|
Antimycin A from Streptomyces sp.
|
Inhibitor of electron transfer at complex III. Induces apoptosis.
|
|
|
|
|
|
A6191
|
|
Antipain dihydrochloride from microbial source protease inhibitor
|
Reversible inhibitor of serine/cysteine proteases and some trypsin-like serine proteases. Its action resembles leupeptin; however, its plasmin inhibition is less and its cathepsin A inhibition is more than that observed with leupeptin. Chronic administration of antipain can reduce the frequency of chemically induced transformation in BALB/c-/3T3 cells.1
|
|
|
|
|
|
A4727
|
|
Antisauvagine-30 trifluoroacetate salt
|
High-affinity antagonist for Corticotropin-releasing factor (CRF) receptor type 2 (CRF(2)).
|
human ... CRHR2(1395) mouse ... CRHR2(12922) rat ... CRHR2(64680)
|
|
|
|
|
A9024
|
|
α1-Antitrypsin from human plasma salt-free, lyophilized powder
|
1-4 mg will inhibit 1.0 mg of trypsin with activity of 10,000 BAEE units per mg protein. 2-6 mg will inhibit approx. 1.0 mg of α-chymotrypsin with activity of 40-50 BTEE units per mg protein. Serine protease inhibitor; inhibits trypsin, chymotrypsin and pancreatic and granulocytic elastase, and acrosin. Effective concentration equimolar with proteinase.The effects of hereditary α1-antitrypsin deficiency and certain autoimmune states result from uncontrolled proteolysis in vivo. Direct α1-antitrypsin replacement therapy has shown promise in animal models of Type 1 diabetes.1
|
human ... ELA2(1991), SERPINA1(5265)
|
|
|
|
|
A6150
|
|
α1-Antitrypsin from human plasma salt-free, lyophilized powder
|
5-10 mg will inhibit 1.0 mg of trypsin with activity of 10,000 BAEE units per mg protein. 5-10 mg will inhibit approx. 1.0 mg of α-chymotrypsin with activity of 40-50 BTEE units per mg protein. Serine protease inhibitor; inhibits trypsin, chymotrypsin and pancreatic and granulocytic elastase, and acrosin. Effective concentration equimolar with proteinase.The effects of hereditary α1-antitrypsin deficiency and certain autoimmune states result from uncontrolled proteolysis in vivo. Direct α1-antitrypsin replacement therapy has shown promise in animal models of Type 1 diabetes.1
|
human ... ELA2(1991), ELANE(1991), SERPINA1(5265)
|
|
|
|
|
A1289
|
|
Apamin from bee venom, ≥95% (HPLC)
|
The only polypeptide neurotoxin that is known to pass the blood-brain barrier. Blocks ATP-type Ca+2-activated K+ channels.
|
rat ... Kcnn1(54261)
|
|
|
|
|
A9459
|
|
Apamin synthetic, ≥97% (HPLC)
|
The only polypeptide neurotoxin that is known to pass the blood-brain barrier. Blocks ATP-type Ca+2-activated K+ channels.
|
rat ... Kcnn1(54261)
|
|
|
|
|
A7361
|
|
2R, 4R-APDC monohydrate ≥98% (HPLC)
|
2R,4R-APDC is a Group II mGluR metabotropic glutamate receptor.
|
|
|
|
|
|
A6469
|
|
Apelin-13 trifluoroacetate salt ≥95%
|
Synthetic endogenous peptide agonist for the human APJ receptor, a putative receptor protein related to the angiotensin receptor (AT1). This peptide exerted an acidification-rate-promoting activity in CHO cells expressing the APJ receptor with a median effective concentration (EC50) value of 0.37 nM. Blocks HIV-1 and HIV-2 entry into cells expressing the APJ receptor.
|
human ... APLN(8862)
|
|
|
|
|
A2478
|
|
APHA Compound 8 ≥98% (HPLC), solid
|
One of a class of aroyl pyrrole hydroxy amide (APHA) compounds showing histone deacetylase (HDAC) inhibition, Compound 8 is the most potent and HDAC class I-selective.1
|
|
|
|
|
|
A0781
|
|
Aphidicolin from Nigrospora sphaerica ≥98% (HPLC), powder
|
Aphidicolin is an antibiotic, a potent antiviral and antimitotic agent and DNA polymerase inhibitor.
|
human ... POLA1(5422), POLD1(5424), POLG(5428)
|
|
|
|
|
A8851
|
|
Apicidin ≥98% (HPLC), from microbial
|
Apicidin is a cyclic tetrapeptide that inhibits histone deacetylase. Apicidin has antiproliferative activity on various cancer cell lines and HeLa cells, accompanied by cell arrest at the G1 phase. It has been shown to induce selective changes in the expression of p21 and gelsolin, induce apoptosis in HL60 cells, and exhibit antiprotozoal, antiparasitic, and potential antimalarial properties.
|
|
|
|
|
|
A3145
|
|
Apigenin ≥97% (TLC), from parsley, powder
|
A plant flavonoid that has been found to inhibit cell proliferation by arresting the cell cycle at the G2/M phase. Inhibition of growth through cell cycle arrest and induction of apoptosis appear to be related to induction of p53.Inhibits PMA-mediated tumor promotion by inhibiting protein kinase C1 and the resulting suppression of oncogene expression. It has also been reported to inhibit topoisomerase I-catalyzed DNA re-ligation and enhance gap junctional intercellular communication.
|
human ... ADORA3(140), CDC2(983), CDK5(1020), CDK6(1021), CYP1A2(1544), ESR1(2099), ESR2(2100), GSK3A(2931) mouse ... Hexa(15211) rat ... Adora1(29290), Adora2a(25369), Il4(287287), Tnf(24835)
|
|
|
|
|
10798
|
|
Apigenin ≥95.0% (HPLC)
|
A plant flavonoid that has been found to inhibit cell proliferation by arresting the cell cycle at the G2/M phase. Inhibition of growth through cell cycle arrest and induction of apoptosis appear to be related to induction of p53.Inhibits PMA-mediated tumor promotion by inhibiting protein kinase C1 and the resulting suppression of oncogene expression. It has also been reported to inhibit topoisomerase I-catalyzed DNA re-ligation and enhance gap junctional intercellular communication.
|
human ... ADORA3(140), CDC2(983), CDK5(1020), CDK6(1021), CYP1A2(1544), ESR1(2099), ESR2(2100), GSK3A(2931) mouse ... Hexa(15211) rat ... Adora1(29290), Adora2a(25369), Il4(287287), Tnf(24835)
|
|
|
|
|
A3641
|
|
Apoferritin from equine spleen 0.2 μm filtered
|
This protein shell of ferritin lacking iron is widely used for the calibration of gel filtration columns and sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis.1 It is very abundant in beta-cells of the pancreas where it acts as an anti-oxidant.2 When added to cultured endothelial cells apoferritin is taken up in a dose-responsive manner and appears to protect the cells from oxidant-mediated cytolysis. 3
|
|
|
|
|
|
A3660
|
|
Apoferritin from equine spleen
|
|
|
|
|
|
|
D043
|
|
(S)-(+)-Apomorphine hydrochloride hydrate solid
|
Dopamine receptor antagonist; inactive as an agonist.
|
|
|
|
|
|
A4393
|
|
R-(−)-Apomorphine hydrochloride hemihydrate calcined, ≥98.5%
|
Nonselective dopamine agonist; causes nausea and emesis.
|
human ... DRD1(1812), DRD2(1813), DRD3(1814), DRD4(1815), DRD5(1816)
|
|
|
|
|
A7606
|
|
Aprindine hydrochloride ≥98% (HPLC), solid
|
Aprindine hydrochloride is a class Ib antiarrhythmic and hERG channel blocker. Aprindine shows structure similarities to lidocaine and procainamide and is effective in treatment of patients with ventricular premature depolarizations, ventricular tachycardia, and supraventricular arrhythmias. Aprindine inhibits the activation of bovine brain cyclic 3′:5′-nucleotide phosphodiesterase (EC 3.1.4.17) by calmodulin and inhibits calmodulin-stimulated Ca-ATPase (ATP phosphohydrolase EC 3.6.1.3) activity.
|
|
|
|
|
|
A6103
|
|
Aprotinin bovine recombinant, expressed in Nicotiana, ≥5 TIU/mg protein, ≥98% (SDS-PAGE)
|
Aprotinin is a competitive serine protease inhibitor that inhibits trypsin, chymotrypsin, kallikrein and plasmin. It had earned a place as an antiinflammatory and antithrombotic adjunct to cardiac surgery, but its value has been called into question.1Aprotinin forms stable complexes with and blocks the active sites of enzymes. Binding is reversible with most aprotinin-protease complexes dissociating at pH >10 or <3. Effective concentration equimolar with protease.
|
cow ... PTI(404172)
|
|
|
|
|
10820
|
|
Aprotinin from bovine lung lyophilized, ~80% (HPCE), crystalline (fine), white, ≥3500 U/mg
|
|
cow ... PTI(404172)
|
|
|
|
|
A6279
|
|
Aprotinin from bovine lung saline solution, 3-7 TIU/mg protein
|
|
cow ... PTI(404172)
|
|
|
|
|
A1153
|
|
Aprotinin from bovine lung lyophilized powder, 3-8 TIU/mg solid
|
|
cow ... PTI(404172)
|
|
|
|
|
A4529
|
|
Aprotinin from bovine lung lyophilized powder, 3-7 TIU/mg solid
|
Binding is reversible with most aprotinin-protease complexes dissociating at pH > 10 or < 3. Effective concentration equimolar with protease. Aprotinin is a monomeric globular polypeptide that is derived from bovine lung. It has a molecular weight of 6512 and consists of 16 different amino acid types arranged in a chain 58 residues long 1.
|
cow ... PTI(404172)
|
|
|
|
|
A3428
|
|
Aprotinin from bovine lung lyophilized powder, 3-8 TIU/mg solid, BioReagent, suitable for cell culture
|
|
cow ... PTI(404172)
|
|
|
|
|
A3886
|
|
Aprotinin from bovine lung
|
|
cow ... PTI(404172)
|
|
|
|
|
A9236
|
|
AQ4 ≥98% (HPLC)
|
AQ4 is a chemically stable cytotoxic agent which acts as a topoisomerase II inhibitor and DNA intercalator. The compound is a potent cytotoxic agent in many human tumor lines, including those derived from human pancreatic adenocarcinomas. The compound N-oxide is a hypoxia activated prodrug of topoisomerase-targeting.
|
|
|
|
|
|
A4233
|
|
Ara-G hydrate ≥98% (HPLC), solid
|
Ara-G is an inducer of apoptosis; inhibitor of DNA synthesis; antineoplastic; and antimetabolite. Ara-G is converted by cellular kinases to the active 5′-triphosphate, Ara-GTP. Incorporation of Ara-GTP into DNA leads to inhibition of DNA synthesis and apoptosis.
|
|
|
|
|
|
A3230
|
|
AR-A014418 ≥98% (HPLC), solid
|
Glycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer′s disease. GSK3 inhibitor, AR-A014418, inhibits GSK3 (IC50 = 104 nM), in an ATP-competitive manner (Ki = 38 nM). AR-A014418 does not significantly inhibit cdk2 or cdk5 (IC50 > 100 μM) or 26 other kinases, demonstrating high specificity for GSK3.
|
|
|
|
|
|
A9673
|
|
Arachidonic acid from porcine liver, ≥99% (GC), liquid
|
Arachidonic acid (AA) is an unsaturated ω6 fatty acid constituent of the phospholipids of cell membranes. Phospholipase A2 releases AA from the membrane phospholipids in response to inflammation. AA is subsequently metabolized to prostaglandins and thromboxanes by at least two cyclooxygenase (COX) isoforms, to leukotrienes and lipoxins by lipoxygenases, and to epoxyeicosatrienoic acids via cytochrome p450-catalyzed metabolism. AA and its metabolites play important roles in a variety of biological processes, including signal transduction, smooth muscle contraction, chemotaxis, cell proliferation and differentiation, and apoptosis. AA has been demonstrated to bind to the a subunit of G protein and inhibit the activity of Ras GTPase-activating proteins (GAPs). Cellular uptake of AA is energy dependent and involves protein-facilitated transport across the plasma membrane. Arachidonic acid stimulates adhesion of MDA-MB-435 human metastatic cancer cells to extracellular matrix molecules (collagen IV and vitronectin) .
|
|
|
|
|
|
A3555
|
|
Arachidonic acid from porcine liver, BioReagent, suitable for cell culture, ≥99% (GC)
|
Arachidonic acid (AA) is an unsaturated ω6 fatty acid constituent of the phospholipids of cell membranes. Phospholipase A2 releases AA from the membrane phospholipids in response to inflammation. AA is subsequently metabolized to prostaglandins and thromboxanes by at least two cyclooxygenase (COX) isoforms, to leukotrienes and lipoxins by lipoxygenases, and to epoxyeicosatrienoic acids via cytochrome p450-catalyzed metabolism. AA and its metabolites play important roles in a variety of biological processes, including signal transduction, smooth muscle contraction, chemotaxis, cell proliferation and differentiation, and apoptosis. AA has been demonstrated to bind to the a subunit of G protein and inhibit the activity of Ras GTPase-activating proteins (GAPs). Cellular uptake of AA is energy dependent and involves protein-facilitated transport across the plasma membrane. Arachidonic acid stimulates adhesion of MDA-MB-435 human metastatic cancer cells to extracellular matrix molecules (collagen IV and vitronectin) .
|
|
|
|
|
|
A3925
|
|
Arachidonic acid from porcine liver, ≥85% (capillary GC), liquid
|
Arachidonic acid (AA) is an unsaturated ω6 fatty acid constituent of the phospholipids of cell membranes. Phospholipase A2 releases AA from the membrane phospholipids in response to inflammation. AA is subsequently metabolized to prostaglandins and thromboxanes by at least two cyclooxygenase (COX) isoforms, to leukotrienes and lipoxins by lipoxygenases, and to epoxyeicosatrienoic acids via cytochrome p450-catalyzed metabolism. AA and its metabolites play important roles in a variety of biological processes, including signal transduction, smooth muscle contraction, chemotaxis, cell proliferation and differentiation, and apoptosis. AA has been demonstrated to bind to the a subunit of G protein and inhibit the activity of Ras GTPase-activating proteins (GAPs). Cellular uptake of AA is energy dependent and involves protein-facilitated transport across the plasma membrane. Arachidonic acid stimulates adhesion of MDA-MB-435 human metastatic cancer cells to extracellular matrix molecules (collagen IV and vitronectin) .
|
|
|
|
|
|
10931
|
|
Arachidonic acid >95.0% (GC)
|
Arachidonic acid (AA) is an unsaturated ω6 fatty acid constituent of the phospholipids of cell membranes. Phospholipase A2 releases AA from the membrane phospholipids in response to inflammation. AA is subsequently metabolized to prostaglandins and thromboxanes by at least two cyclooxygenase (COX) isoforms, to leukotrienes and lipoxins by lipoxygenases, and to epoxyeicosatrienoic acids via cytochrome p450-catalyzed metabolism. AA and its metabolites play important roles in a variety of biological processes, including signal transduction, smooth muscle contraction, chemotaxis, cell proliferation and differentiation, and apoptosis. AA has been demonstrated to bind to the a subunit of G protein and inhibit the activity of Ras GTPase-activating proteins (GAPs). Cellular uptake of AA is energy dependent and involves protein-facilitated transport across the plasma membrane. Arachidonic acid stimulates adhesion of MDA-MB-435 human metastatic cancer cells to extracellular matrix molecules (collagen IV and vitronectin) .
|
|
|
|
|
|
A8798
|
|
Arachidonic acid sodium salt from porcine liver, ≥99% (capillary GC), waxy solid
|
Released arachidonic acid (AA) reacts with molecular oxygen nonenzymatically, through oxidative stress, and enzymatically through the action of oxygenase enzymes.2 AA is oxidized to prostaglandins and thromboxanes by at least two cyclooxygenase (COX) isoforms, to leukotrienes and lipoxins by lipoxygenases, and to epoxyeicosatrienoic acids via cytochrome p450-catalyzed metabolism. Cellular uptake of AA is energy dependent and involves protein-facilitated transport across the plasma membrane.
|
|
|
|
|
|
A4425
|
|
Arachidonic acid sodium salt from porcine liver, ~90% (capillary GC), waxy solid
|
|
|
|
|
|
|
A8848
|
|
Arachidonoyl dopamine ≥98% (HPLC), ethanol solution
|
AA-DA competitively inhibits fatty acid amide hydrolase (IC50 = approx. 22 μM) from N18TG2 neuroblastoma cells and inhibits binding (Ki = 0.25 μM) of the selective cannabinoid receptor subtype 1 (CB1) ligand, [3H]SR141716A, to rat brain membrane. AA-DA also inhibits the anandamide membrane transporter in BL-2H3 basophilic leukemia and C6 glioma cells.1 AA-DA has at least a 40 fold greater selectivity for CB1 than CB2 receptors in rat brain membranes and has been shown to be more potent than anandamide as a CB1 agonist in undifferentiated N18TG2 neuroblastoma cells. AA-DA induces hypothermia and immobility, and decreases spontaneous activity and pain perception in mice and rats, which supports its action as a CB1 agonist in vivo.1,2 AA-DA has been shown to inhibit (IC50 = 0.25 μM) proliferation of human breast MCF-7 cancer cells.
|
|
|
|
|
|
A7357
|
|
Arachidonoylserotonin ≥98% (HPLC), oil
|
Arachidonoylserotonin is a Fatty Acid Amide Hydrolase (FAAH) Inhibitor and Transient Receptor Potential Vanilloid-Type I (TRPV1) Antagonist. FAAH and TRPV1 are targets for chronic pain treatment. Arachidonylserotonin is a dual target agent and is analgesic in rodents.
|
|
|
|
|
|
A9719
|
|
Arachidonyl-2′-chloroethylamide hydrate ≥97% (HPLC), oil
|
Potent and selective neuronal CB1 cannabinoid receptor agonist.
|
mouse ... Cnr1(12801), Cnr2(12802) rat ... Cnr1(25248)
|
|
|
|
|
A0580
|
|
Arachidonylethanolamide ~98% (TLC), oil
|
An arachidonic acid derivative that is an endogenous ligand for the CB cannabinoid receptor and for the VR1 vanilloid receptor. Inhibits calcium currents in neuroblastomas and neurons. Activates the MAP kinase signaling pathway. Inhibits proliferation and induces apoptosis of lymphocytes and human breast cancer cells.
|
rat ... Cnr1(25248)
|
|
|
|
|
A8973
|
|
2-Arachidonyl glycerol acetonitrile solution, ~10 mg/mL, ≥98% (HPLC)
|
Endogenous cannabinoid receptor agonist.
|
human ... FAAH(2166) rat ... Cnr1(25248), Cnr2(57302)
|
|
|
|
|
A231
|
|
Arachidonyl trifluoromethyl ketone oil, ≥97% (NMR)
|
Inhibits anandamide hydrolysis in vitro; inhibits phospholipase A2.
|
human ... PLA2G1B(5319)
|
|
|
|
|
A0384
|
|
Arcaine sulfate salt
|
Potent antagonist at the polyamine site of the NMDA glutamate receptor.
|
human ... GRIN1(2902), GRIN2A(2903), GRIN2B(2904), GRIN2C(2905), GRIN2D(2906), GRINA(2907)
|
|
|
|
|
A140
|
|
Arecaidine propargyl ester hydrobromide solid
|
Potent muscarinic acetylcholine receptor agonist exhibiting slight selectivity for M2 receptors; inactive at nicotinic receptors.
|
human ... CHRM2(1129)
|
|
|
|
|
A2793
|
|
Arg-Arg-Arg-Glu-Glu-Glu-Thr-Glu-Glu-Glu lyophilized powder
|
Specific substrate for casein kinase II.
|
human ... CSNK2A1(1457), CSNK2A2(1459), CSNK2B(1460) mouse ... CSNK2A1(12995), CSNK2A2(13000), CSNK2B(13001) rat ... CSNK2A1(116549), CSNK2B(81650)
|
|
|
|
|
A9041
|
|
Arg-Gly-Asp-Ser ≥95% (HPLC)
|
|
human ... ITGA2B(3674), ITGB3(3690) mouse ... Itgb3(16416)
|
|
|
|
|
A5686
|
|
Arg-Gly-Glu-Ser acetate salt ≥95% (HPLC)
|
Inhibitor of platelet aggregation
|
human ... FN1(2335) mouse ... FN1(14268) rat ... FN1(25661)
|
|
|
|
|
A2646
|
|
D-Arginine ≥98% (TLC)
|
|
rat ... Ppm1a(24666)
|
|
|
|
|
A6757
|
|
D-Arginine monohydrochloride ≥98% (TLC)
|
|
|
|
|
|
|
W381918
|
|
L-Arginine ≥98.5%, FCC
|
Substrate of nitric oxide synthase, which is converted to citrulline and nitric oxide (NO). Induces insulin release by a nitric oxide-dependent mechanism.
|
human ... NOS1(4842), NOS2(4843) rat ... Ppm1a(24666)
|
|
|
|
|
A5006
|
|
L-Arginine reagent grade, ≥98% (TLC), powder
|
Substrate of nitric oxide synthase, which is converted to citrulline and nitric oxide (NO). Induces insulin release by a nitric oxide-dependent mechanism.
|
human ... NOS1(4842), NOS2(4843) rat ... Ppm1a(24666)
|
|
|
|
|
A8094
|
|
L-Arginine from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%
|
Substrate of nitric oxide synthase, which is converted to citrulline and nitric oxide (NO). Induces insulin release by a nitric oxide-dependent mechanism.
|
human ... NOS1(4842), NOS2(4843) rat ... Ppm1a(24666)
|
|
|
|
|
A4474
|
|
L-Arginine PharmaGrade, Ajinomoto, EP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture
|
Substrate of nitric oxide synthase, which is converted to citrulline and nitric oxide (NO). Induces insulin release by a nitric oxide-dependent mechanism.
|
human ... NOS1(4842), NOS2(4843) rat ... Ppm1a(24666)
|
|
|
|
|
11009
|
|
L-Arginine BioUltra, ≥99.5% (NT)
|
Substrate of nitric oxide synthase, which is converted to citrulline and nitric oxide (NO). Induces insulin release by a nitric oxide-dependent mechanism.
|
human ... NOS1(4842), NOS2(4843) rat ... Ppm1a(24666)
|
|
|
|
|
A5131
|
|
L-Arginine monohydrochloride reagent grade, ≥98% (TLC), powder
|
Substrate of nitric oxide synthase, which is converted to citrulline and nitric oxide (NO). Induces insulin release by a nitric oxide-dependent mechanism.
|
|
|
|
|
|
A6969
|
|
L-Arginine monohydrochloride not synthetic, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
|
Substrate of nitric oxide synthase, which is converted to citrulline and nitric oxide (NO). Induces insulin release by a nitric oxide-dependent mechanism.
|
|
|
|
|
|
A4599
|
|
L-Arginine monohydrochloride Ajinomoto Amino Acid, EP, JP, USP, suitable for manufacturing use, ≥98.5%, from non-animal source
|
Substrate of nitric oxide synthase, which is converted to citrulline and nitric oxide (NO). Induces insulin release by a nitric oxide-dependent mechanism.
|
|
|
|
|
|
11039
|
|
L-Arginine monohydrochloride BioUltra, ≥99.5% (AT)
|
Substrate of nitric oxide synthase, which is converted to citrulline and nitric oxide (NO). Induces insulin release by a nitric oxide-dependent mechanism.
|
|
|
|
|
|
A5512
|
|
Aristolochic acid I powder
|
Potent phospholipase A2 inhibitor, including calcium ionophore-induced phospholipase A2 activity in neutrophils. Kidney tumor initiator in experimental animal model.1
|
|
|
|
|
|
A9451
|
|
Aristolochic acid I sodium salt powder, ≥97%
|
Component of some Chinese herbal medicines, and responsible for their nephrotoxicity. Prodrug activated by reduction of the nitro group to an amine, which forms cytotoxic DNA adducts.1
|
|
|
|
|
|
SML0178
|
|
ARL-17477 dihydrochloride hydrate ≥98% (HPLC)
|
ARL-17477 is an nNOS specific inhibitor. The IC50 against rat nNOS is 35 nM and it has 100-fold selectivity over endothelial and inducible isoforms. ARL-17477 penetrates the brain, and reduces infarct size and reduces cerebral blood flow in several different rodent models of ischemic brain injury.
|
|
|
|
|
|
A265
|
|
ARL 67156 trisodium salt hydrate ≥98% (HPLC), solid
|
ecto-ATPase inhibitor; prevents metabolism of P2 purinoceptor agonists.
|
human ... ENTPD2(954)
|
|
|
|
|
SML0039
|
|
Armodafinil ≥98% (HPLC)
|
Armodafinil is the R isomer and longer-lasting isomer of racemic modafinil. It is a psychostimulant wake-promoting agent developed for the treatment of narcolepsy, shift work sleep disorder and excessive daytime sleepiness associated with obstructive sleep apnea
|
|
|
|
|
|
A8356
|
|
ARP 101 ≥98% (HPLC), solid
|
ARP 101 is a MMP-2 selective inhibitor (Gelatinase A, EC 3.4.24.24; TBE-1; LG4A; MONA; Type IV Collagenase). ARP 101 has diverse physiological roles including wound healing, cancer metastasis, angiogenesis, tissue remodeling in development and embryogenesis. IC50 = 0.81 nM on MMP-2.
|
|
|
|
|
|
A9361
|
|
Artemether ≥98% (HPLC)
|
Artemether is a methyl ether derivative of artemisinin. It is used against multi-drug resistant strains of the malaria parasite, Plasmodium falciparum, and shows potential in treatment of schistosomiasis.1
|
|
|
|
|
|
A8981
|
|
AS-252424 ≥98% (HPLC), solid
|
AS-252424 is a potent and selective phosphoinositide 3-kinase PI3Kγ inhibitor with IC50 = 30 nM in a mouse model.
|
|
|
|
|
|
SML0104
|
|
Ascochlorin ≥98% (HPLC), from Verticillium hemipterigenum
|
Ascochlorin is an isoprenoid antibiotic produced by Verticillium hemipterigenum, initially identified as an antiviral and antitumor agent. Research also indicates that ascochlorin inhibits the Qi and Qo quinone binding sites of the mitochondria cytochrom bc1 complex.1 Moreover, ascochlorin activates p53, probably as a result of its inhibitory effect on mitochondrial respiration.2, In addition, ascochlorin has the ability to suppress the nuclear subscription enzyme protein-1, a nuclear transcription factor activator, which leads to suppression of the extra-cellular enzyme, matrix metalloproteinase-9 (MMP9).3, The regulation of MMP is implicated in renal development, macrophage differentiation, atherosclerosis, inflammation, rheumatoid arthritis, and tumor invasion. Ascochlorin was also found to be effective against Mx-1, an estrogen lacking breast cancer cell line.4
|
|
|
|
|
|
A3835
|
|
Ascomycin from Streptomyces hygroscopicus var. ascomyceticus
|
Strong immunosuppressant; inhibits allogenic T-lymphocyte proliferation. It binds with high affinity to FKBP and inhibits calcineurin phosphatase in the nM range.
|
|
|
|
|
|
A5960
|
|
L-Ascorbic acid BioXtra, ≥99.0%, crystalline
|
Ascorbic Acid, also known as Vitamin C, is a six-carbon lactone produced by plants and some animal species but not by humans and other primates. Ascorbic acid functions as an enzymatic cofactor for multiple enzymes, serving as an electron donor for monooxygenases and dioxygenases. Ascorbic acid also functions as a powerful antioxidant, particularly in regards to reactive oxygen species.
|
human ... SLC23A2(9962)
|
|
|
|
|
A7506
|
|
L-Ascorbic acid reagent grade, crystalline
|
Ascorbic Acid, also known as Vitamin C, is a six-carbon lactone produced by plants and some animal species but not by humans and other primates. Ascorbic acid functions as an enzymatic cofactor for multiple enzymes, serving as an electron donor for monooxygenases and dioxygenases. Ascorbic acid also functions as a powerful antioxidant, particularly in regards to reactive oxygen species.
|
human ... SLC23A2(9962)
|
|
|
|
|
A0278
|
|
L-Ascorbic acid reagent grade
|
Ascorbic Acid, also known as Vitamin C, is a six-carbon lactone produced by plants and some animal species but not by humans and other primates. Ascorbic acid functions as an enzymatic cofactor for multiple enzymes, serving as an electron donor for monooxygenases and dioxygenases. Ascorbic acid also functions as a powerful antioxidant, particularly in regards to reactive oxygen species.
|
human ... SLC23A2(9962)
|
|
|
|
|
A4403
|
|
L-Ascorbic acid powder, cell culture tested, γ-irradiated
|
|
human ... SLC23A2(9962)
|
|
|
|
|
A4544
|
|
L-Ascorbic acid suitable for cell culture, suitable for plant cell culture, ≥98%
|
Ascorbic Acid, also known as Vitamin C, is a six-carbon lactone produced by plants and some animal species but not by humans and other primates. Ascorbic acid functions as an enzymatic cofactor for multiple enzymes, serving as an electron donor for monooxygenases and dioxygenases. Ascorbic acid also functions as a powerful antioxidant, particularly in regards to reactive oxygen species.
|
human ... SLC23A2(9962)
|
|
|
|
|
A2218
|
|
L-Ascorbic acid meets USP testing specifications
|
Ascorbic Acid, also known as Vitamin C, is a six-carbon lactone produced by plants and some animal species but not by humans and other primates. Ascorbic acid functions as an enzymatic cofactor for multiple enzymes, serving as an electron donor for monooxygenases and dioxygenases. Ascorbic acid also functions as a powerful antioxidant, particularly in regards to reactive oxygen species.
|
human ... SLC23A2(9962)
|
|
|
|
|
A2174
|
|
L-Ascorbic acid plant cell culture tested
|
|
human ... SLC23A2(9962)
|
|
|
|
|
A2343
|
|
L-Ascorbic acid meets USP testing specifications
|
Ascorbic Acid, also known as Vitamin C, is a six-carbon lactone produced by plants and some animal species but not by humans and other primates. Ascorbic acid functions as an enzymatic cofactor for multiple enzymes, serving as an electron donor for monooxygenases and dioxygenases. Ascorbic acid also functions as a powerful antioxidant, particularly in regards to reactive oxygen species.
|
human ... SLC23A2(9962)
|
|
|
|
|
95209
|
|
L-Ascorbic acid BioUltra, ≥99.5% (RT)
|
L-Ascorbic acid (Vitamin C) is a water soluble molecule use in a wide variety of applications, including cell culture, as a reducing agent that helps reduce oxidative stress. L-Ascorbate can be regenerated by biological systems.
|
human ... SLC23A2(9962)
|
|
|
|
|
33034
|
|
L-Ascorbic acid puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., 99.7-100.5% (oxidimetric)
|
|
human ... SLC23A2(9962)
|
|
|
|
|
95210
|
|
L-Ascorbic acid puriss. p.a., ≥99.0% (RT)
|
|
human ... SLC23A2(9962)
|
|
|
|
|
95212
|
|
L-Ascorbic acid Ph Eur
|
Ascorbic Acid, also known as Vitamin C, is a six-carbon lactone produced by plants and some animal species but not by humans and other primates. Ascorbic acid functions as an enzymatic cofactor for multiple enzymes, serving as an electron donor for monooxygenases and dioxygenases. Ascorbic acid also functions as a powerful antioxidant, particularly in regards to reactive oxygen species.
|
human ... SLC23A2(9962)
|
|
|
|
|
47863
|
|
L-Ascorbic acid analytical standard
|
|
human ... SLC23A2(9962)
|
|
|
|
|
255564
|
|
L-Ascorbic acid ACS reagent, ≥99%
|
|
human ... SLC23A2(9962)
|
|
|
|
|
A92902
|
|
L-Ascorbic acid 99%
|
Ascorbic Acid, also known as Vitamin C, is a six-carbon lactone produced by plants and some animal species but not by humans and other primates. Ascorbic acid functions as an enzymatic cofactor for multiple enzymes, serving as an electron donor for monooxygenases and dioxygenases. Ascorbic acid also functions as a powerful antioxidant, particularly in regards to reactive oxygen species.
|
human ... SLC23A2(9962)
|
|
|
|
|
W210901
|
|
L-Ascorbic acid FCC
|
|
human ... SLC23A2(9962)
|
|
|
|
|
A7861
|
|
Asenapine maleate ≥98% (HPLC)
|
Asenapine maleate is a 5-HT receptor antagonist (5-HT1A,1B, 5-HT2A, 2B, 2C, 5-HT5A, 5-HT6 and 5-HT7), a D2 antagonist, and an antipsychotic.
|
|
|
|
|
|
G3018
|
|
Asialoganglioside GM1 from bovine brain ~98%, lyophilized powder
|
Removing the sialic acid from monosialoganglioside GM1 inhibits its ability to bind cholera toxin. Asialoganglioside GM1 does not block the binding of cholera toxin to cellular GM1.
|
|
|
|
|
|
G9402
|
|
Asialoganglioside GM1 from bovine brain lyophilized powder, BioXtra, γ-irradiated, suitable for cell culture
|
Removing the sialic acid from monosialoganglioside GM1 inhibits its ability to bind cholera toxin. Asialoganglioside GM1 does not block the binding of cholera toxin to cellular GM1.
|
|
|
|
|
|
G9398
|
|
Asialoganglioside-GM2 from bovine brain ~95%, lyophilized powder
|
Degraded form of Asialoganglioside-GM1 ganglioside.
|
|
|
|
|
|
219096
|
|
D-Aspartic acid ReagentPlus®, 99%
|
|
rat ... Slc1a3(29483)
|
|
|
|
|
A5474
|
|
L-Aspartic acid PharmaGrade, Ajinomoto, EP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture
|
Principal neurotransmitter for fast synaptic excitation.
|
human ... CA1(759), CA2(760) rat ... Grin2a(24409)
|
|
|
|
|
A9256
|
|
L-Aspartic acid reagent grade, ≥98% (TLC)
|
Principal neurotransmitter for fast synaptic excitation.
|
human ... CA1(759), CA2(760) rat ... Grin2a(24409)
|
|
|
|
|
A8949
|
|
L-Aspartic acid BioXtra, ≥99% (TLC)
|
L-Aspartic acid is a natural proteinogenic amino acid that may be used in the formulation of cell culture media and in protein and polypeptide synthesis systems and procedures. L-Aspartic acid, an NMDA receptor agonist and non-specific glutamate receptor agonist, is used to differentiate and study the mechanisms of NMDA receptors. Principal neurotransmitter for fast synaptic excitation.
|
human ... CA1(759), CA2(760) rat ... Grin2a(24409)
|
|
|
|
|
A7219
|
|
L-Aspartic acid from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%
|
Principal neurotransmitter for fast synaptic excitation.
|
human ... CA1(759), CA2(760) rat ... Grin2a(24409)
|
|
|
|
|
A4534
|
|
L-Aspartic acid BioReagent, suitable for cell culture, suitable for insect cell culture
|
Principal neurotransmitter for fast synaptic excitation.
|
human ... CA1(759), CA2(760) rat ... Grin2a(24409)
|
|
|
|
|
11189
|
|
L-Aspartic acid BioUltra, ≥99.5% (T)
|
Principal neurotransmitter for fast synaptic excitation.
|
human ... CA1(759), CA2(760) rat ... Grin2a(24409)
|
|
|
|
|
A9506
|
|
L-Aspartic acid hemimagnesium salt hydrate ≥98% (TLC)
|
Principal neurotransmitter for fast synaptic excitation.
|
human ... GRIN2A(2903) rat ... GRIN2A(14811)
|
|
|
|
|
A6558
|
|
L-Aspartic acid potassium salt ≥98% (TLC)
|
Principal neurotransmitter for fast synaptic excitation.
|
|
|
|
|
|
A6683
|
|
L-Aspartic acid sodium salt monohydrate ≥98% (TLC)
|
Principal neurotransmitter for fast synaptic excitation.
|
human ... GRIN2A(2903) rat ... GRIN2A(14811)
|
|
|
|
|
11195
|
|
L-Aspartic acid sodium salt monohydrate ≥99.0% (NT)
|
Principal neurotransmitter for fast synaptic excitation.
|
|
|
|
|
|
A2093
|
|
Aspirin meets USP testing specifications
|
Blocks the production of prostaglandins by inhibiting cyclooxygenase (prostaglandin H synthase), with greater selectivity toward the COX-1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in platelets that blocks thromboxane production and platelet aggregation. Chemopreventive against colorectal and other solid tumors.
|
human ... ITGA2B(3674), PTGS1(5742), PTGS2(5743)
|
|
|
|
|
A4933
|
|
Astressin ≥90% (HPLC)
|
Highly potent CRF antagonist.
|
human ... CRH(1392) mouse ... CRH(12918) rat ... CRH(81648)
|
|
|
|
|
A5227
|
|
Astressin2B trifluoroacetate salt ≥98% (HPLC)
|
Astressin2B is a CRH2 corticotropin-releasing hormone receptor antagonist.Corticotropin Releasing Factor (CRF), its family members, and competitive antagonists such as astressin assume an alpha-helical conformation when interacting with their receptors.
|
human ... CRHR2(1395) mouse ... CRHR2(12922) rat ... CRHR2(64680)
|
|
|
|
|
A3355
|
|
ATC0175 ≥98% (HPLC), solid
|
ATC0175 is a non-peptide, orally active melanin-concentrating hormone receptor 1 (MCHR1) antagonist. Non-peptide, orally active melanin-concentrating hormone receptor 1 (MCHR1) antagonist.
|
|
|
|
|
|
A7655
|
|
Atenolol ≥98% (TLC), powder
|
Selective β1-adrenoceptor antagonist; antihypertensive; antianginal; antiarrhythmic.
|
human ... ADRB1(153) rat ... Adrb1(24925)
|
|
|
|
|
330884
|
|
(R)-(+)-Atenolol 99%
|
|
|
|
|
|
|
A143
|
|
(S)-(−)-Atenolol powder
|
β1-Adrenergic receptor antagonist; active enantiomer of atenolol.
|
human ... ADRB1(153)
|
|
|
|
|
330892
|
|
(S)-(−)-Atenolol 99%
|
|
|
|
|
|
|
PZ0001
|
|
Atorvastatin calcium salt trihydrate ≥98% (HPLC)
|
Atorvastatin calcium salt trihydrate is a specific inhibitor of HMG-CoA reductase. HMG-CoA reductase is the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early step in cholesterol biosynthesis. Atorvastatin is used in the treatment of hypercholesterolemia.
|
|
|
|
|
|
A3480
|
|
Atosiban ≥98% (HPLC)
|
Atosiban is a peptide oxytocin receptor antagonist.
|
human ... AVPR1A(552), OXTR(5021) rat ... Oxtr(25342)
|
|
|
|
|
A7986
|
|
Atovaquone ≥98% (HPLC)
|
Atovaquone is an anti-protozoal mitochondrial electron transport inhibitor; Antimalarial; Antipneumocystic, and has also been used to treat toxoplasmosis. It is an analog of protozoan mitochondrial protein ubiquinone, and acts by inhibiting the cytochrome bc(1) complex via interactions with the Rieske iron-sulfur protein and cytochrome b in the ubiquinol oxidation pocket.
|
|
|
|
|
|
A263
|
|
ATPA solid
|
Selective kainate receptor agonist.
|
human ... GRIK1(2897) rat ... Gria1(50592), Grik1(29559), Grin2a(24409)
|
|
|
|
|
A7845
|
|
ATPO solid
|
Competitive antagonist at GluR1-4 (AMPA-preferring) receptors.
|
human ... GRIA1(2890), GRIA2(2891), GRIA3(2892), GRIA4(2893) rat ... Gria1(50592), Grik1(29559), Grin2a(24409)
|
|
|
|
|
45330
|
|
Atrazine PESTANAL®, analytical standard
|
|
mouse ... Esr1(13982)
|
|
|
|
|
49085
|
|
Atrazine analytical standard
|
|
mouse ... Esr1(13982)
|
|
|
|
|
48187
|
|
Atrazine solution 1000 μg/mL in methyl tert-butyl ether, analytical standard
|
|
mouse ... Esr1(13982)
|
|
|
|
|
36667
|
|
Atrazine-desethyl-desisopropyl PESTANAL®, analytical standard
|
|
mouse ... Esr1(13982)
|
|
|
|
|
A0132
|
|
Atropine ≥99% (TLC), powder
|
Competitive nonselective antagonist at central and peripheral muscarinic acetylcholine receptors.
|
human ... CHRM1(1128), CHRM2(1129), CHRM4(1132), CHRM5(1133), LOC730413(730413) mouse ... Chrm1(12669) rat ... Chrm1(25229), Chrm2(81645), Chrm3(24260), Drd2(24318), Htr1a(24473)
|
|
|
|
|
A2468
|
|
Atropine meets USP testing specifications
|
Competitive nonselective antagonist at central and peripheral muscarinic acetylcholine receptors.
|
human ... CHRM1(1128), CHRM2(1129), CHRM3(1131), CHRM4(1132), CHRM5(1133) mouse ... Chrm1(12669) rat ... Chrm1(25229), Chrm2(81645), Chrm3(24260), Drd2(24318), Htr1a(24473)
|
|
|
|
|
11332
|
|
Atropine sulfate salt monohydrate Ph Eur
|
Competitive nonselective antagonist at central and peripheral muscarinic acetylcholine receptors.
|
|
|
|
|
|
A0257
|
|
Atropine sulfate salt monohydrate ≥97% (TLC), crystalline
|
Competitive nonselective antagonist at central and peripheral muscarinic acetylcholine receptors.
|
human ... CHRM1(1128), CHRM2(1129), CHRM3(1131), CHRM4(1132), CHRM5(1133)
|
|
|
|
|
SML0177
|
|
AUDA ≥98% (HPLC)
|
AUDA is a potent inhibitor of soluble epoxide hydrolase
|
|
|
|
|
|
A1895
|
|
Aurintricarboxylic acid practical grade, ≥85% (titration), powder
|
Readily polymerizes in aqueous solution, forming a stable free radical that inhibits protein-nucleic acid interactions. It is a potent inhibitor of ribonuclease and topoisomerase II by preventing the binding of the nucleic acid to the enzyme. It stimulates tyrosine phosphorylation processes including the Jak2/STAT5 pathway in NB2 lymphoma cells, ErbB4 in neuroblastoma cells, and MAP kinases, Shc proteins, phosphatidylinositide 3-kinase and phospholipase Cγ in PC12 cells. Inhibits apoptosis. It prevents down-regulation of Ca2+ -impermeable GluR2 receptors and inhibits calpain, a Ca2+ -activated protease that is activated during apoptosis.
|
|
|
|
|
|
A0606
|
|
Aurothioglucose hydrate ≥97% (titration)
|
Aurothioglucose, a gold compound used clinically to treat rheumatoid arthritis, has recently been found to be a potent PKCiota-Par6 interaction inhibitor, with an IC50 approximately 1 μM. Disruption of this interaction disrupts a rac1 signaling pathway that is required for transformed growth in non-small-cell lung cancer.
|
|
|
|
|
|
A0591
|
|
Autocamtide 2 trifluoroacetate salt ≥97% (HPLC)
|
|
human ... CAMK1(8536) mouse ... CAMK1(52163) rat ... CAMK1(171503)
|
|
|
|
|
A4308
|
|
Autocamtide 2-related inhibitory peptide ≥97% (HPLC), lyophilized powder
|
Potent inhibitor of calmodulin-depentent protein kinase II.
|
human ... CAMK2A(815), CAMK2B(816), CAMK2D(817) mouse ... CAMK2A(12322), CAMK2B(12323), CAMK2D(108058) rat ... CAMK2A(25400), CAMK2B(24245), CAMK2D(24246)
|
|
|
|
|
PZ0190
|
|
Avasimibe ≥98% (HPLC)
|
Avasimibe (CI-1011) is an orally bioavailable Acyl-CoA:Cholesterol O-Acyltransferase (ACAT) inhibitor. It was originally developed as an antilepic drug, and was shown to significantly reduce plasma total triglyceride and VLDL-cholesterol, but later clinical trials were disappointing. ACAT has also been investigated as a potential therapeutic target for Alzheimer′s disease. Recent studies have looked at the effects of avasimibe in reducing amyloid pathology by limiting generation and increasing clearance of diffusible amyloid-beta (Abeta).
|
|
|
|
|
|
PZ0123
|
|
Avridine ≥97% (HPLC)
|
Avridine is a potent synthetic adjuvant that can induce arthritis in most rat strains; immunomodulator and interferon-inducing.
|
|
|
|
|
|
PZ0193
|
|
Axitinib ≥98% (HPLC)
|
Axitinib (AG-013736) is an orally available, potent (picomolar) and selective tyrosine kinase inhibitor that blocks VEGF receptors 1, 2 and 3. The drug blocks VEGF-mediated endothelial cell survival, tube formation, and downstream signaling through endothelial nitric oxide synthase, Akt and extracellular signal-regulated kinase.
|
|
|
|
|
|
A7231
|
|
AZ11645373 ≥98% (HPLC), solid
|
AZ11645373 is a selective and potent human P2X7 purinoceptor antagonist. KB values range from 5-20 nM for human P2X7 receptor inhibition. It is 500-fold less effective ats an inhibitor of rat P2X7 receptor responses.
|
|
|
|
|
|
A2385
|
|
5-Azacytidine ≥98% (HPLC)
|
A potent growth inhibitor and cytotoxic agent; inhibits DNA methyltransferase, an important regulatory mechanism of gene expression, gene activation and silencing. Causes DNA demethylation or hemi-demethylation, creating openings that allow transcription factors to bind to DNA and reactivate tumor suppressor genes.
|
human ... DNMT1(1786), DNMT3A(1788), DNMT3B(1789)
|
|
|
|
|
A3656
|
|
5-Aza-2′-deoxycytidine ≥97%
|
5′-Azadeoxycytidine causes DNA demethylation or hemi-demethylation. DNA demethylation can regulate gene expression by "opening" the chromatin structure detectable as increased nuclease sensitivity. This remodeling of chromatin structure allows transcription factors to bind to the promoter regions, assembly of the transcription complex, and gene expression.
|
|
|
|
|
|
A6850
|
|
Azelaoyl PAF 10 mg/mL in ethanol
|
Potent PPARγ agonist.
|
|
|
|
|
|
A7611
|
|
Azelastine hydrochloride ≥98% (HPLC)
|
H1 histamine receptor antagonist; NF-kB activator.
|
|
|
|
|
|
A7106
|
|
Azelnidipine ≥98% (HPLC), powder
|
Azelnidipine, a novel dihydropyridine derivative, is a L-type calcium channel blocker and antihypertensive. Unlike other L-type calcium channel blockers, azelnidipine causes minimal stimulation of the sympathetic nervous system despite its significant depressor effect. Azelnidipine may have a protective role in inflammation in atherosclerosis.
|
|
|
|
|
|
A0760
|
|
L-Azetidine-2-carboxylic acid ≥99%
|
L-Azetidine-2-carboxylic acid is an inhibitor of collagen synthesis that is anti-angiogenic. It is a four-membered ring analog of L-proline that causes protein misconstruction when incorporated instead of proline.
|
|
|
|
|
|
A2169
|
|
3′-Azido-3′-deoxythymidine ≥98% (HPLC)
|
Reverse transcriptase inhibitor active against HIV-1 virus.
|
human ... HIVE1(3095) mouse ... Slc29a1(63959)
|
|
|
|
|
PZ0007
|
|
Azithromycin dihydrate ≥98% (HPLC)
|
Azithromycin dihydrate is a macrolide antibiotic, azalide subclass. It binds to the 50S subunit of the 70S bacterial ribosomes and inhibits RNA-dependent protein synthesis in bacterial cells. Azithromycin also has anti-immunomodulatory/anti-inflammatory properties, which make it useful in treating cystic fibrosis.
|
|
|
|
|
|
SML0242
|
|
AZ-MTAB ≥98% (HPLC)
|
AZ-MTAB is a potent, short acting κ-opioid receptor (KOR) selective antagonist.
|
|
|
|
|